Atox Bio, a Ness Ziona, Israel-based developer of therapeutics for severe infections, raised up to $23m in Series E investment.
The round was led by SR One with participation by Lundbeckfond Ventures and OrbiMed Israel.
The company intends to use the funds to initiate a late stage clinical study of AB103, a novel therapy for the treatment of Necrotizing Soft Tissue Infections. The study is expected to start in the second half of 2015.
Led by Dan Teleman, CEO Atox Bio advances AB103, a novel immunomodulator discovered by Prof. Raymond Kaempfer and Dr. Gila Arad and licensed from Yissum, the technology transfer company of the Hebrew University, is a rationally designed, short peptide that modulates the host’s inflammatory response through binding to the CD28 dimer interface. It offers a new approach in the treatment of infectious diseases by modulating (not inhibiting) the host immune system.